The pooled outcomes for HOMA-IR in 5 RCTs were consistent with those of Han Y et al. [40], who reported that HOMA-IR showed better improvements with GLP-1 receptor agonists than with metformin in patients with polycystic ovary syndrome. Here, GLP1R is linked to polycystic ovary syndrome.